AgyPharma

Agy Therapeutics is a South San Francisco-based biotechnology company focused on developing transformative therapies for neuroregeneration and neuroprotection. The company utilizes a proprietary platform to identify molecular pathways within the neuro-vascular unit (NVU) that drive brain repair and recovery following acute injury or chronic degeneration. Their lead programs, including AGY-010 and AGY-020, are designed to restore neurological function in patients suffering from stroke and traumatic brain injury. Founded by industry veterans from Genentech and Halozyme, Agy is backed by leading venture capital firms such as 5AM Ventures and ARCH Venture Partners. The company's approach represents a shift from traditional neuroprotection to active neuroregeneration, aiming to address significant unmet needs in neurology.